Sarepta Therapeutics (SRPT) FY2024 results: revenue $1.9 billion, up 53.0% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $1.9 billion for fiscal 2024, the year ended 31 December 2024, up 53.0% on the year before. Net income was $235 million, and diluted earnings per share $2.34. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2025.
Revenue
$1.9 billion
+53.0% on the year
FY2017FY2024
Operating margin
11.5%
-21.5% a year earlier
FY2017FY2024
Net income
$235 million
FY2017FY2024
Diluted EPS
$2.34
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-206
-501
-325
Capital expenditure
137
76.1
30.8
+80.0%
Free cash flow
-343
-577
-356
Free cash flow margin
-18.0%
-46.4%
-38.2%
Cash from investing
756
-166
-1,047
Cash from financing
125
125
233
-0.2%
Depreciation and amortisation
37.7
44.4
41.9
-15.0%
Share-based compensation
184
183
233
+1.0%
Buybacks
0.0
0.0
n/a
Diluted shares, weighted
108m
92m
88m
+16.8%
Shares outstanding at period end
97m
94m
88m
+3.4%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
1,528
859
385
+77.8%
Debt
1,137
1,238
1,544
-8.1%
Operating lease liabilities
192
141
57.6
+36.5%
Other liabilities
1,106
1,026
1,142
+7.8%
Total liabilities and equity
3,963
3,265
3,128
+21.4%
Fixed assets
340
227
180
+49.8%
Intangible assets
26.9
29.6
7.6
-9.2%
Investments
385
1,248
1,023
-69.2%
Cash and equivalents
1,103
428
967
+157.5%
Receivables
602
400
215
+50.4%
Inventory
750
323
204
+132.3%
Other assets
756
608
533
+24.3%
Total assets
3,963
3,265
3,128
+21.4%
10-K for the year ended 31 December 2024, filed 28 February 2025: the filing.